Search

Your search keyword '"Kurk, Sophie A."' showing total 35 results
Start Over Author "Kurk, Sophie A."
35 results on '"Kurk, Sophie A."'

2. Use of automated assessment for determining associations of low muscle mass and muscle loss with overall survival in patients with colorectal cancer – A validation study

Author

Medisch Oncologische Disciplines, Epi Kanker Team B, Cancer, Arts-assistenten Radiotherapie, MS Medische Oncologie, MS Radiologie, Circulatory Health, Epi Kanker, JC onderzoeksprogramma Cancer, Smit, Karel C., Derksen, Jeroen W.G., Kurk, Sophie A., Moeskops, Pim, Koopman, Miriam, Veldhuis, Wouter B., May, Anne M., Medisch Oncologische Disciplines, Epi Kanker Team B, Cancer, Arts-assistenten Radiotherapie, MS Medische Oncologie, MS Radiologie, Circulatory Health, Epi Kanker, JC onderzoeksprogramma Cancer, Smit, Karel C., Derksen, Jeroen W.G., Kurk, Sophie A., Moeskops, Pim, Koopman, Miriam, Veldhuis, Wouter B., and May, Anne M.

Published
2024

4. Subgroup analyses of the phase 3 CAIRO3 trial: Association of number and total volume of metastases on survival in patients with metastatic colorectal cancer based on a deep-learning automatic segmentation model.

Author

Zwart, Koen, primary, Zeeuw, Michiel J., additional, Stehouwer, Bertine L., additional, Al-Toma, Dania, additional, Kurk, Sophie, additional, Braat, Manon N.G.J.A., additional, de Jong, Pim A., additional, Lagendijk, Jan J.W., additional, May, Anne M., additional, Koopman, Miriam, additional, Punt, Cornelis J. A., additional, Kazemier, Geert, additional, and Bol, Guus, additional

Published
2024
Full Text
View/download PDF

7. Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics

Author

Apotheek Opleiding, Cancer, Arts-assistenten Radiotherapie, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Externen Med. Onco, Apotheek O&O&O, Molenaar-Kuijsten, Laura, Jacobs, Bart Albertus Wilhelmus, Kurk, Sophie Alberdine, May, Anne Maria, Dorlo, Thomas Petrus Catharina, Beijnen, Jacob Hendrik, Steeghs, Neeltje, Huitema, Alwin Dagmar Redmar, Apotheek Opleiding, Cancer, Arts-assistenten Radiotherapie, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Externen Med. Onco, Apotheek O&O&O, Molenaar-Kuijsten, Laura, Jacobs, Bart Albertus Wilhelmus, Kurk, Sophie Alberdine, May, Anne Maria, Dorlo, Thomas Petrus Catharina, Beijnen, Jacob Hendrik, Steeghs, Neeltje, and Huitema, Alwin Dagmar Redmar

Published
2021

8. Role of Up-Front Primary Tumor Resection and Tumor Sidedness in the Survival of Synchronous Metastatic Colon Cancer Patients

Author

Cancer, Onderzoek Medische Oncologie, Arts-assistenten Radiotherapie, Epi Kanker Team B, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Epi Kanker Team A, MS Medische Oncologie, van der Kruijssen, Dave E W, van Rooijen, Karlijn L, Kurk, Sophie A, de Wilt, Johannes HW, Punt, Cornelis J A, Vink, Geraldine R, Elias, Sjoerd G, Koopman, Miriam, Cancer, Onderzoek Medische Oncologie, Arts-assistenten Radiotherapie, Epi Kanker Team B, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Epi Kanker Team A, MS Medische Oncologie, van der Kruijssen, Dave E W, van Rooijen, Karlijn L, Kurk, Sophie A, de Wilt, Johannes HW, Punt, Cornelis J A, Vink, Geraldine R, Elias, Sjoerd G, and Koopman, Miriam

Published
2021

10. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer : Secondary analysis of the phase 3 CAIRO3 trial

Author

Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2020

11. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial

Author

Arts-assistenten Radiotherapie, Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, Researchgr. Systems Radiology, Regenerative Medicine and Stem Cells, Infection & Immunity, Circulatory Health, MS Medische Oncologie, Epidemiology & Health Economics, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Arts-assistenten Radiotherapie, Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, Researchgr. Systems Radiology, Regenerative Medicine and Stem Cells, Infection & Immunity, Circulatory Health, MS Medische Oncologie, Epidemiology & Health Economics, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Creemers, Geert-Jan M, Erdkamp, Frans L G, de Jongh, Felix E, Kint, Peter A M, Poppema, Boelo J, Radema, Sandra A, Simkens, Lieke H J, Tanis, Bea C, Tjin-A-Ton, Manuel L R, Van Der Velden, Ankie, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2020

12. The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer

Author

Onderzoek Medische Oncologie, Cancer, Arts-assistenten Radiotherapie, JC onderzoeksprogramma Cancer, Epi Kanker Team 1, Epi Kanker Team A, MS Medische Oncologie, Epidemiology & Health Economics, Derksen, Jeroen W G, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, Jourdan, Marion, van der Velden, Ankie M T, Nieboer, Peter, de Jong, Robert S, Honkoop, Aafke H, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Onderzoek Medische Oncologie, Cancer, Arts-assistenten Radiotherapie, JC onderzoeksprogramma Cancer, Epi Kanker Team 1, Epi Kanker Team A, MS Medische Oncologie, Epidemiology & Health Economics, Derksen, Jeroen W G, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, Jourdan, Marion, van der Velden, Ankie M T, Nieboer, Peter, de Jong, Robert S, Honkoop, Aafke H, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2020

13. The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer

Author

Derksen, Jeroen W.G., primary, Kurk, Sophie A., additional, Peeters, Petra H.M., additional, Dorresteijn, Bram, additional, Jourdan, Marion, additional, Velden, Ankie M.T., additional, Nieboer, Peter, additional, Jong, Robert S., additional, Honkoop, Aafke H., additional, Punt, Cornelis J.A., additional, Koopman, Miriam, additional, and May, Anne M., additional

Published
2020
Full Text
View/download PDF

14. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial

Author

Kurk, Sophie A., primary, Peeters, Petra H. M., additional, Dorresteijn, Bram, additional, de Jong, Pim A., additional, Jourdan, Marion, additional, Creemers, Geert‐Jan M., additional, Erdkamp, Frans L. G., additional, de Jongh, Felix E., additional, Kint, Peter A. M., additional, Poppema, Boelo J., additional, Radema, Sandra A., additional, Simkens, Lieke H. J., additional, Tanis, Bea C., additional, Tjin‐A‐Ton, Manuel L. R., additional, Van Der Velden, Ankie, additional, Punt, Cornelis J. A., additional, Koopman, Miriam, additional, and May, Anne M., additional

Published
2019
Full Text
View/download PDF

15. Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients

Author

Kurk, Sophie, primary, Peeters, Petra, additional, Stellato, Rebecca, additional, Dorresteijn, B., additional, Jong, Pim, additional, Jourdan, Marion, additional, Creemers, Geert‐Jan, additional, Erdkamp, Frans, additional, Jongh, Felix, additional, Kint, Peter, additional, Simkens, Lieke, additional, Tanis, Bea, additional, Tjin‐A‐Ton, Manuel, additional, Van Der Velden, Ankie, additional, Punt, Cornelis, additional, Koopman, Miriam, additional, and May, Anne, additional

Published
2019
Full Text
View/download PDF

17. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients

Author

Kurk, Sophie, Peeters, Petra, Stellato, Rebecca, Dorresteijn, B, de Jong, Pim, Jourdan, Marion, Creemers, Geert-Jan, Erdkamp, Frans, de Jongh, Felix, Kint, Peter, Simkens, Lieke, Tanis, Bea, Tjin-A-Ton, Manuel, Van Der Velden, Ankie, Punt, Cornelis, Koopman, Miriam, May, Anne, Kurk, Sophie, Peeters, Petra, Stellato, Rebecca, Dorresteijn, B, de Jong, Pim, Jourdan, Marion, Creemers, Geert-Jan, Erdkamp, Frans, de Jongh, Felix, Kint, Peter, Simkens, Lieke, Tanis, Bea, Tjin-A-Ton, Manuel, Van Der Velden, Ankie, Punt, Cornelis, Koopman, Miriam, and May, Anne

Published
2019

20. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients

Author

Arts-assistenten Radiotherapie, Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, Biostatistiek Onderwijs, JC onderzoeksprogramma Methodologie, Researchgr. Systems Radiology, MS Medische Oncologie, Epidemiology & Health Economics, Kurk, Sophie, Peeters, Petra, Stellato, Rebecca, Dorresteijn, B, de Jong, Pim, Jourdan, Marion, Creemers, Geert-Jan, Erdkamp, Frans, de Jongh, Felix, Kint, Peter, Simkens, Lieke, Tanis, Bea, Tjin-A-Ton, Manuel, Van Der Velden, Ankie, Punt, Cornelis, Koopman, Miriam, May, Anne, Arts-assistenten Radiotherapie, Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, Biostatistiek Onderwijs, JC onderzoeksprogramma Methodologie, Researchgr. Systems Radiology, MS Medische Oncologie, Epidemiology & Health Economics, Kurk, Sophie, Peeters, Petra, Stellato, Rebecca, Dorresteijn, B, de Jong, Pim, Jourdan, Marion, Creemers, Geert-Jan, Erdkamp, Frans, de Jongh, Felix, Kint, Peter, Simkens, Lieke, Tanis, Bea, Tjin-A-Ton, Manuel, Van Der Velden, Ankie, Punt, Cornelis, Koopman, Miriam, and May, Anne

Published
2019

21. Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer

Author

Onderzoek Medische Oncologie, Cancer, Arts-assistenten Radiotherapie, Epi Kanker Team 1, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Epidemiology & Health Economics, Derksen, Jeroen W G, Kurk, Sophie A, Oskam, Marieke J, Peeters, Petra H M, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Onderzoek Medische Oncologie, Cancer, Arts-assistenten Radiotherapie, Epi Kanker Team 1, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Epidemiology & Health Economics, Derksen, Jeroen W G, Kurk, Sophie A, Oskam, Marieke J, Peeters, Petra H M, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2019

22. Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients

Author

Arts-assistenten Radiotherapie, Biostatistiek Onderwijs, JC onderzoeksprogramma Methodologie, Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Epidemiology & Health Economics, Kurk, Sophie A, Stellato, Rebecca K, Peeters, Petra H M, Dorresteijn, Bram, Jourdan, Marion, Oskam, Marieke J, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Arts-assistenten Radiotherapie, Biostatistiek Onderwijs, JC onderzoeksprogramma Methodologie, Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Epidemiology & Health Economics, Kurk, Sophie A, Stellato, Rebecca K, Peeters, Petra H M, Dorresteijn, Bram, Jourdan, Marion, Oskam, Marieke J, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2019

23. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy

Author

Onderzoek Medische Oncologie, Dijksterhuis, Willemieke P M, Pruijt, Maarten J, van der Woude, Stephanie O, Klaassen, Remy, Kurk, Sophie A, van Oijen, Martijn G H, van Laarhoven, Hanneke W M, Onderzoek Medische Oncologie, Dijksterhuis, Willemieke P M, Pruijt, Maarten J, van der Woude, Stephanie O, Klaassen, Remy, Kurk, Sophie A, van Oijen, Martijn G H, and van Laarhoven, Hanneke W M

Published
2019

24. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients

Author

Kurk, Sophie A., Peeters, Petra H.M., Dorresteijn, Bram, de Jong, Pim A., Jourdan, Marion, Kuijf, Hugo J., Punt, Cornelis J.A., Koopman, Miriam, May, Anne M., Oncology, and CCA - Cancer Treatment and Quality of Life

Subjects
Male, Sarcopenia, lcsh:Diseases of the musculoskeletal system, Skeletal muscle, Body composition, lcsh:QM1-695, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Humans, Body Weights and Measures, Neoplasm Metastasis, Muscle, Skeletal, Aged, Neoplasm Staging, Aged, 80 and over, Metastatic colorectal cancer, Palliative Care, lcsh:Human anatomy, Original Articles, Organ Size, Middle Aged, Original Article, Female, lcsh:RC925-935, Colorectal Neoplasms, Tomography, X-Ray Computed
Abstract

Background Observational studies suggest that loss of skeletal muscle mass (SMM) is associated with chemotherapy‐related toxicity, poor quality of life, and poor survival in metastatic colorectal cancer (mCRC) patients. Little is known about the evolution of SMM during palliative systemic therapy. We investigated changes in SMM during various consecutive palliative systemic treatment regimens using repeated abdominal computed tomography scans of mCRC patients who participated in the randomized phase 3 CAIRO3 study. Methods In the CAIRO3 study, mCRC patients with stable disease or better after 6 cycles of first‐line treatment with capecitabine + oxaliplatin + bevacizumab (CAPOX‐B) were randomized between maintenance treatment with capecitabine + bevacizumab (CAP‐B) or observation. Upon first disease progression, in both groups, CAPOX‐B or other treatment was reintroduced until the second disease progression, which was the primary study endpoint. We analysed 1355 computed tomography scans of 450 (81%) CAIRO3 patients (64 ± 9.0 years, CAP‐B n = 223; observation n = 227) for SMM at four time points (i.e. prior to the start of pre‐randomization initial treatment, at randomization, and at first and at second disease progression) using the Slice‐o‐matic software and single slice evaluation at the lumbar 3 level. By using accepted and widely used formulas, whole body SMM was calculated. A linear mixed effects model, adjusted for relevant confounders, was used to assess SMM changes for the total group and within and between study arms. Results During 6 cycles of initial treatment with CAPOX‐B prior to randomization, SMM decreased significantly in all patients [CAP‐B arm: −0.53 kg (95% CI −1.12; −0.07) and observation arm: −0.85 kg (−1.45; −0.25)]. After randomization, SMM recovered during CAP‐B treatment by 1.32 kg (0.73; 1.90) and observation by 1.20 kg (0.63; 1.78) (median time from randomization to first disease progression 8.6 and 4.1 months for CAP‐B arm and observation arm, respectively). After first progression and during reintroduction treatment with CAPOX‐B or other treatment, SMM again decreased significantly and comparable in both arms, CAP‐B: −2.71 kg (−3.37; −2.03), and observation: −2.01 kg (−2.64; −1.41) (median time from first progression until second progression CAP‐B arm: 4.7 months and observation arm: 6.6 months). Conclusions This longitudinal study provides a unique insight in SMM changes in mCRC patients during palliative systemic treatment regimens, including observation. Our data show that muscle loss is reversible and may be influenced by the intensity of systemic regimens. Although studies have shown prognostic capacity for SMM, the effects of subsequent changes in SMM are unknown and may be clues for new future therapeutic interventions.

Published
2018

27. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients

Author

Julius Centrum, Onderzoek Medische Oncologie, Cancer, JC onderzoeksprogramma Kanker, Epi Kanker Team 1, UMC Utrecht, Researchgr. Systems Radiology, Infection & Immunity, Circulatory Health, Beeldverwerking ISI, Brain, MS Medische Oncologie, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Kuijf, Hugo J, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Julius Centrum, Onderzoek Medische Oncologie, Cancer, JC onderzoeksprogramma Kanker, Epi Kanker Team 1, UMC Utrecht, Researchgr. Systems Radiology, Infection & Immunity, Circulatory Health, Beeldverwerking ISI, Brain, MS Medische Oncologie, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, de Jong, Pim A, Jourdan, Marion, Kuijf, Hugo J, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2018

28. Impact of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) on time to progression and overall survival (OS) in metastatic colorectal cancer (mCRC) patients.

Author

Kurk, Sophie, primary, Peeters, Petra H.M., additional, Stellato, Rebecca K., additional, Dorresteijn, Bram, additional, Jourdan, Marion, additional, Creemers, Geert-Jan, additional, Erdkamp, Frans, additional, de Jongh, Felix E., additional, Kint, Petrus Alouisius Maria, additional, Poppema, Boelo Jan, additional, Radema, Sandra Anita, additional, Simkens, Lieke H, additional, Tanis, Bea, additional, Tjin-A-Ton, Manuel Lucien Roy, additional, Van Der Velden, Ankie, additional, Punt, Cornelis J. A., additional, Koopman, Miriam, additional, and May, Anne Maria, additional

Published
2017
Full Text
View/download PDF

29. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.

Author

Kurk, Sophie A., Peeters, Petra H. M., Dorresteijn, Bram, Jong, Pim A., Jourdan, Marion, Creemers, Geert‐Jan M., Erdkamp, Frans L. G., Jongh, Felix E., Kint, Peter A. M., Poppema, Boelo J., Radema, Sandra A., Simkens, Lieke H. J., Tanis, Bea C., Tjin‐A‐Ton, Manuel L. R., Van Der Velden, Ankie, Punt, Cornelis J. A., Koopman, Miriam, and May, Anne M.

Subjects
*SKELETAL muscle, *COLORECTAL cancer, *METASTASIS, *SECONDARY analysis, *BODY mass index
Abstract

Background: Low skeletal muscle index (SMI) in metastatic colorectal cancer (mCRC) patients is associated with poor outcomes. The prognostic impact of SMI changes during consecutive palliative systemic treatments is unknown. Methods: This is a retrospective analysis of the phase 3 CAIRO3 study. The CAIRO3 study randomized 557 patients between maintenance capecitabine + bevacizumab (CAP‐B) or observation, after six cycles capecitabine + oxaliplatin + bevacizumab (CAPOX‐B). Upon first disease progression (PD1), CAPOX‐B was reintroduced until second progression (PD2). SMI was assessed by computed tomography (CT) (total 1355 scans). SMI and body mass index (BMI) changes were analyzed for three time‐periods; p1: during initial CAPOX‐B, p2: randomization to PD1, and p3: PD1 to PD2. The association between absolute and change in SMI and BMI (both per 1 standard deviation) during p1‐p3, with PD1, PD2, and survival was studied by Cox regression models. Results: This analysis included 450 of the 557 patients randomized in the CAIRO3 study. Mean SMI decreased during p1: mean −0.6 SMI units [95% CI −1.07;‐0.26] and p3: −2.2 units [−2.7;‐1.8], whereas during p2, SMI increased + 1.2 units [0.8‐1.6]. BMI changes did not reflect changes in SMI. SMI loss during p2 and p3 was significantly associated with shorter survival (HR 1.19 [1.09‐1.35]; 1.54 [1.31‐1.79], respectively). Sarcopenia at PD1 was significantly associated with early PD2 (HR 1.40 [1.10‐1.70]). BMI loss independent of SMI loss was only associated with shorter overall survival during p3 (HR 1.35 [1.14‐1.63]). Conclusions: In mCRC patients, SMI loss during palliative systemic treatment was related with early disease progression and reduced survival. BMI did not reflect changes in SMI and could not identify patients at risk of poor outcome during early treatment lines. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

31. A Systematic Review of the Diagnostic Value of CT Imaging in Diagnosing Otosclerosis

Author

MS KNO, Brain, MS Medische Oncologie, ZL Algemene en Acute Nec Medisch, Zorgeenheid KNO Medisch, Wegner, Inge, van Waes, Anne M A, Bittermann, Arnold J, Buitinck, Sophie H, Dekker, Caroline F, Kurk, Sophie A, Rados, Matea, Grolman, Wilko, MS KNO, Brain, MS Medische Oncologie, ZL Algemene en Acute Nec Medisch, Zorgeenheid KNO Medisch, Wegner, Inge, van Waes, Anne M A, Bittermann, Arnold J, Buitinck, Sophie H, Dekker, Caroline F, Kurk, Sophie A, Rados, Matea, and Grolman, Wilko

Published
2016

32. Abstract 1827: The prospective Dutch colorectal cancer cohort: A prospective nation-wide observational cohort study

Author

Coebergh van den Braak, Robert R.J., primary, Vink, Geraldine R., additional, van Oijen, Martijn G.H., additional, de Noo, Mirre E., additional, Kurk, Sophie A., additional, Burbach, Maarten J.P., additional, Couwenberg, Alice M., additional, May, Anne M., additional, Verkooijen, Helena M., additional, Meijer, Gerrit A., additional, and Koopman, Miriam, additional

Published
2016
Full Text
View/download PDF

34. Feasibility of 7-T fluorine magnetic resonance spectroscopic imaging (19F MRSI) for TAS-102 metabolite detection in the liver of patients with metastatic colorectal cancer.

Author

Kurk, Sophie A., Steensma, Bart R., May, Anne M., Koopman, Miriam, Hoogduin, Hans M., van der Velden, Tijl A., Klomp, Dennis W. J., and van der Kemp, Wybe J. M.

Subjects
NUCLEAR magnetic resonance spectroscopy, METABOLITES, COLON cancer, BIOLOGICAL tags, ORGANOIDS
Abstract

Trifluridine/tipiracil (TAS-102) has shown a significant overall survival benefit in patients with heavily pre-treated metastatic colorectal cancer. However, predicting treatment response and toxicity in individual patients remains challenging. Fluorine (19F)-containing drugs can be detected with magnetic resonance spectroscopy (MRS) to determine the metabolic rates and the biodistribution of the drug in normal and tumour tissue, which are related to treatment efficacy and toxicity. This is the first study to investigate the potential of 7-T 19F-MRS to detect TAS-102 metabolites in humans. We demonstrate that, with the used setup, TAS-102 is not detectable in liver metastases of metastatic colorectal cancer patients on a normal treatment schedule. Therefore, 19F-MRS TAS-102 metabolite detection is not yet useful for the clinical early prediction of treatment response. As 19F-MRS is able to detect TAS-102 in phantom and murine models, the use of 19F-MRS remains a potential tool to noninvasively detect and possibly monitor the metabolism when higher dosages of TAS-102 are administered, for example in organoid and animal studies. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

35. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.

Author

Kurk SA, Peeters PHM, Dorresteijn B, de Jong PA, Jourdan M, Kuijf HJ, Punt CJA, Koopman M, and May AM

Subjects
Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Body Weights and Measures, Colorectal Neoplasms therapy, Female, Humans, Male, Middle Aged, Muscle, Skeletal diagnostic imaging, Neoplasm Metastasis, Neoplasm Staging, Organ Size, Palliative Care methods, Tomography, X-Ray Computed, Colorectal Neoplasms metabolism, Colorectal Neoplasms pathology, Muscle, Skeletal pathology
Abstract

Background: Observational studies suggest that loss of skeletal muscle mass (SMM) is associated with chemotherapy-related toxicity, poor quality of life, and poor survival in metastatic colorectal cancer (mCRC) patients. Little is known about the evolution of SMM during palliative systemic therapy. We investigated changes in SMM during various consecutive palliative systemic treatment regimens using repeated abdominal computed tomography scans of mCRC patients who participated in the randomized phase 3 CAIRO3 study., Methods: In the CAIRO3 study, mCRC patients with stable disease or better after 6 cycles of first-line treatment with capecitabine + oxaliplatin + bevacizumab (CAPOX-B) were randomized between maintenance treatment with capecitabine + bevacizumab (CAP-B) or observation. Upon first disease progression, in both groups, CAPOX-B or other treatment was reintroduced until the second disease progression, which was the primary study endpoint. We analysed 1355 computed tomography scans of 450 (81%) CAIRO3 patients (64 ± 9.0 years, CAP-B n = 223; observation n = 227) for SMM at four time points (i.e. prior to the start of pre-randomization initial treatment, at randomization, and at first and at second disease progression) using the Slice-o-matic software and single slice evaluation at the lumbar 3 level. By using accepted and widely used formulas, whole body SMM was calculated. A linear mixed effects model, adjusted for relevant confounders, was used to assess SMM changes for the total group and within and between study arms., Results: During 6 cycles of initial treatment with CAPOX-B prior to randomization, SMM decreased significantly in all patients [CAP-B arm: -0.53 kg (95% CI -1.12; -0.07) and observation arm: -0.85 kg (-1.45; -0.25)]. After randomization, SMM recovered during CAP-B treatment by 1.32 kg (0.73; 1.90) and observation by 1.20 kg (0.63; 1.78) (median time from randomization to first disease progression 8.6 and 4.1 months for CAP-B arm and observation arm, respectively). After first progression and during reintroduction treatment with CAPOX-B or other treatment, SMM again decreased significantly and comparable in both arms, CAP-B: -2.71 kg (-3.37; -2.03), and observation: -2.01 kg (-2.64; -1.41) (median time from first progression until second progression CAP-B arm: 4.7 months and observation arm: 6.6 months)., Conclusions: This longitudinal study provides a unique insight in SMM changes in mCRC patients during palliative systemic treatment regimens, including observation. Our data show that muscle loss is reversible and may be influenced by the intensity of systemic regimens. Although studies have shown prognostic capacity for SMM, the effects of subsequent changes in SMM are unknown and may be clues for new future therapeutic interventions., (© 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results